Dendritic Cell Membrane-Derived Nanovesicles for Targeted T Cell Activation.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
20 Dec 2022
20 Dec 2022
Historique:
received:
13
07
2022
accepted:
14
11
2022
entrez:
26
12
2022
pubmed:
27
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
T cells play an integral role in the generation of an effective immune response and are responsible for clearing foreign microbes that have bypassed innate immune system defenses and possess cognate antigens. The immune response can be directed toward a desired target through the selective priming and activation of T cells. Due to their ability to activate a T cell response, dendritic cells and endogenous vesicles from dendritic cells are being developed for cancer immunotherapy treatment. However, current platforms, such as exosomes and synthetic nanoparticles, are limited by their production methods and application constraints. Here, we engineer nanovesicles derived from dendritic cell membranes with similar properties as dendritic cell exosomes via nitrogen cavitation. These cell-derived nanovesicles are capable of activating antigen-specific T cells through direct and indirect mechanisms. Additionally, these nanovesicles can be produced in large yields, overcoming production constraints that limit clinical application of alternative immunomodulatory vesicle or nanoparticle-based methods. Thus, dendritic cell-derived nanovesicles generated by nitrogen cavitation show potential as an immunotherapy platform to stimulate and direct T cell response.
Identifiants
pubmed: 36570199
doi: 10.1021/acsomega.2c04420
pmc: PMC9773342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
46222-46233Subventions
Organisme : NCI NIH HHS
ID : P30 CA177558
Pays : United States
Informations de copyright
© 2022 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Adv Sci (Weinh). 2020 Feb 05;7(7):1903301
pubmed: 32274314
Acta Biomater. 2020 Mar 15;105:1-14
pubmed: 32001369
Eur J Immunol. 2004 Jan;34(1):156-64
pubmed: 14971041
J Clin Invest. 2016 Apr 1;126(4):1139-43
pubmed: 27035805
Eur J Immunol. 2004 Feb;34(2):398-407
pubmed: 14768044
Analyst. 2015 Oct 7;140(19):6631-42
pubmed: 26332016
Nanomaterials (Basel). 2020 Sep 15;10(9):
pubmed: 32942556
Nat Immunol. 2002 Dec;3(12):1156-62
pubmed: 12426563
Mol Ther. 2021 May 5;29(5):1729-1743
pubmed: 33484965
J Cell Mol Med. 2018 Mar;22(3):2001-2006
pubmed: 29377463
Chem Rev. 2015 Oct 14;115(19):11147-90
pubmed: 26088284
Blood Cells Mol Dis. 2005 Jul-Aug;35(1):17-20
pubmed: 15932799
Nat Rev Immunol. 2014 Mar;14(3):195-208
pubmed: 24566916
J Immunol. 2011 Mar 1;186(5):2850-9
pubmed: 21263068
J Immunol. 2014 Aug 1;193(3):1006-11
pubmed: 25049431
Blood. 2005 Jul 1;106(1):216-23
pubmed: 15790784
J Extracell Vesicles. 2014 Aug 04;3:
pubmed: 25143819
Methods Enzymol. 2008;438:77-93
pubmed: 18413242
Prog Neurobiol. 2019 Dec;183:101694
pubmed: 31542363
Semin Cell Dev Biol. 2017 Jul;67:29-38
pubmed: 27916565
J Transl Med. 2005 Mar 02;3(1):10
pubmed: 15740633
Nanoscale Res Lett. 2018 Feb 07;13(1):44
pubmed: 29417375
J Transl Med. 2005 Feb 21;3(1):9
pubmed: 15723705
Acta Pharm Sin B. 2022 Aug;12(8):3233-3254
pubmed: 35967284
Blood. 2004 Nov 15;104(10):3257-66
pubmed: 15284116
ACS Omega. 2019 Jul 24;4(7):12657-12664
pubmed: 31460386
Adv Drug Deliv Rev. 2013 Mar;65(3):342-7
pubmed: 22776312
Nat Rev Immunol. 2003 Dec;3(12):973-83
pubmed: 14647479
Semin Immunopathol. 2011 Sep;33(5):419-40
pubmed: 21174094
J Liposome Res. 2009;19(2):85-90
pubmed: 19514998
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156
pubmed: 26928656
J Vis Exp. 2017 Aug 18;(126):
pubmed: 28872138
Blood. 2000 Nov 1;96(9):3102-8
pubmed: 11049990
Nat Med. 1998 May;4(5):594-600
pubmed: 9585234
ACS Omega. 2021 Jan 26;6(5):3847-3857
pubmed: 33585763
Mol Pharm. 2019 Jan 7;16(1):24-40
pubmed: 30513203
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11671-6
pubmed: 16855047
Clin Med Insights Pathol. 2016 Sep 14;9(Suppl 1):1-8
pubmed: 27660518
Cell. 2016 Mar 10;164(6):1226-1232
pubmed: 26967288
BioDrugs. 2020 Oct;34(5):567-586
pubmed: 32754790
Trends Mol Med. 2013 Oct;19(10):625-32
pubmed: 23954168
Adv Healthc Mater. 2019 Feb;8(4):e1801091
pubmed: 30565895
RSC Adv. 2019 Apr 10;9(20):11230-11238
pubmed: 35520256
Front Immunol. 2017 Mar 27;8:327
pubmed: 28396662
Anal Bioanal Chem. 2015 May;407(12):3285-301
pubmed: 25821114
J Immunol. 2004 Jan 1;172(1):292-301
pubmed: 14688337
Oncoimmunology. 2015 Aug 12;5(4):e1071008
pubmed: 27141373
Curr Pharm Des. 2015;21(42):6214-35
pubmed: 26503143
J Biomed Sci. 2018 Dec 24;25(1):91
pubmed: 30580764
Nat Rev Immunol. 2009 Aug;9(8):581-93
pubmed: 19498381
Immunol Rev. 2016 Jul;272(1):97-108
pubmed: 27319345
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S3-23
pubmed: 20176265
Semin Cell Dev Biol. 2015 Apr;40:72-81
pubmed: 25724562
J Proteomics. 2010 Sep 10;73(10):1907-20
pubmed: 20601276
Bioengineering (Basel). 2019 Jan 16;6(1):
pubmed: 30654439
Front Immunol. 2022 Jul 07;13:923598
pubmed: 35874757
Adv Drug Deliv Rev. 2013 Mar;65(3):391-7
pubmed: 22921840